Trials / Unknown
UnknownNCT04275050
A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3303 Tablets
A Phase I, Open-label, Dose Escalation and Expansion Study to Evaluate the Tolerance and Pharmacokinetics of TQB3303 Tablets
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
TQB3303 tablet is a small molecule oral drug inhibiting cyclin-dependent kinases 4 and 6 (CDK4 / 6). Based on current research, overexpression of positive regulatory proteins in the cell cycle is one of the important reasons for resistance to endocrine therapy. CDK4 / 6 is the key regulators of the cell cycle inhibiting tumor cell proliferation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB3303 | TQB3303 tablet is a small molecule oral drug inhibiting cyclin-dependent kinases 4 and 6 (CDK4 / 6). |
Timeline
- Start date
- 2020-04-01
- Primary completion
- 2021-04-01
- Completion
- 2022-04-01
- First posted
- 2020-02-19
- Last updated
- 2020-02-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04275050. Inclusion in this directory is not an endorsement.